The final programme for the ICE-HBV Serum Biomarkers Workshop to be held over Zoom on the 5th and 12th of October 2020 has been released. Please see the attached document for the full programme, objectives and background.
Despite the existence of an excellent preventative vaccine and antiviral therapies which effectively control the virus, chronic hepatitis B affects 257 million people and is one of the leading causes of death worldwide. The global hepatitis B research community is working together with people living with hepatitis B to develop cures and many approaches are currently in early stage clinical trials. Until these cures are available, it is imperative that people are tested and receive the life-saving antiviral treatment to control their HBV infection and prevent liver disease.
ICE-HBV encourages more people to get tested and treated for chronic HBV, and to let people living with HBV know that the global HBV research community is in their corner and is striving for a cure, so we can live a #hepfreefuture